Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Chief Scientific Officer & COO | December 17, 2025 | December 19, 2025 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Chief Scientific Officer & COO | February 07, 2019 | February 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.52 · Expires 2035-12-17 | Direct | 54,000 |
Reported balance
After 2025-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-17 · Grant · Acquired 54,000 · Balance 54,000 F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
Arcturus Therapeutics Ltd.
Report date February 07, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2029-02-06 | Direct | 1,667 |
Reported balance
After 2019-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-07 · Grant · Acquired 1,667 · Balance 1,667 F1: Vesting over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.99 · Expires 2029-02-06 | Direct | 38,333 |
Reported balance
After 2019-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-07 · Grant · Acquired 38,333 · Balance 38,333 F1: Vesting over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2025 Filed Dec 19, 2025 17:21 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0001193805-25-001766 · e665060_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2035-12-17 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 17, 2026, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 16:06 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $16.24 | $0.00 |
DisclosureSEC source: 0001193805-24-001491 · e664084_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-12-16 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 16, 2025, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 21:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 12,000 | $20.76 | $249,121.20 |
DisclosureSEC source: 0001193805-24-001248 · e663956_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,334 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 12,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 15, 2024, with sale prices ranging from $20.03 to $21.12 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 17:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 114 | $45.00 | $5,130.00 |
DisclosureSEC source: 0001193805-24-000768 · e663692_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,334 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the price of 114 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person on June 5, 2024. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 16:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 26,000 | $40.01 | $1,040,234.00 |
DisclosureSEC source: 0001193805-24-000746 · e663681_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 26,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 3, 2024, with sale prices ranging from $40.00 to $40.325 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 16:15 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 17,435 | $35.02 | $610,573.70 |
DisclosureSEC source: 0001193805-24-000452 · e663461_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 473,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 17,435 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 25, 2024, with sale prices ranging from $35.00 to $35.045 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 17:27 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 8,565 | $35.01 | $299,839.24 |
DisclosureSEC source: 0001193805-24-000426 · e619136_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 490,883 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 8,565 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 19, 2024, with sale prices ranging from $35.00 to $35.02 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001193805-23-001629 · e619136_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-12-15 F1 · shares: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 15, 2024, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $18.72 | $93,601.50 |
DisclosureSEC source: 0001193805-23-001470 · e619041_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 1, 2023, with sale prices ranging from $18.39 to $19.27 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 16:06 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $25.61 | $128,061.50 |
DisclosureSEC source: 0001193805-23-001361 · e618979_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 504,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 2, 2023, with sale prices ranging from $25.29 to $26.32 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $31.45 | $157,263.50 |
DisclosureSEC source: 0001193805-23-001249 · e618918_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 509,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 1, 2023, with sale prices ranging from $30.70 to $31.75 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:15 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $34.91 | $174,550.00 |
DisclosureSEC source: 0001193805-23-001075 · e618822_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 514,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on August 1, 2023, with sale prices ranging from $34.44 to $35.70 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 18:50 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 25,000 | $35.01 | $875,250.00 |
DisclosureSEC source: 0001193805-23-001003 · e618783_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 519,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 25,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on July 14, 2023, with sale prices ranging from $35.00 to $35.04 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 7, 2023 06:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $28.75 | $143,750.00 |
DisclosureSEC source: 0001193805-23-000955 · e618766_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 544,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on July 3, 2023, with sale prices ranging from $28.57 to $28.96 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:07 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $27.16 | $135,800.00 |
DisclosureSEC source: 0001193805-23-000824 · e618686_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 549,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on June 1, 2023, with sale prices ranging from $26.87 to $27.54 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 11, 2023 Filed May 12, 2023 16:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 7,925 | $30.24 | $239,652.00 |
DisclosureSEC source: 0001193805-23-000719 · e618625_4-chivukula.xml · nonDerivative · entry 2 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects the weighted average price of 7,925 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on May 11, 2023, with sale prices ranging from $30.035 to $30.48 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 10, 2023 Filed May 12, 2023 16:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 17,075 | $30.00 | $512,250.00 |
DisclosureSEC source: 0001193805-23-000719 · e618625_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,373 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 17,075 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on May 10, 2023, with sale prices ranging from $30.00 to $30.06 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:08 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $25.93 | $129,650.00 |
DisclosureSEC source: 0001193805-23-000656 · e618570_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 579,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions May 1, 2023 with sale prices ranging from $25.39 to $26.58 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:47 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $25.38 | $126,900.00 |
DisclosureSEC source: 0001193805-23-000516 · e618445_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 584,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions April 3, 2023 with sale prices ranging from $23.56 to $26.12 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:34 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 5,000 | $16.07 | $80,350.00 |
DisclosureSEC source: 0001193805-23-000295 · e618338_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 5,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions March 6, 2023 with sale prices ranging from $15.66 to $16.09 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 16:06 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $16.92 | $0.00 |
DisclosureSEC source: 0001193805-22-001714 · e618107_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-12-09 F1 · shares: Represents options to purchase shares of common stock approved by the Board of Directors on December 9, 2022 pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 9, 2023, the first anniversary of the date this award was approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 16:17 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantEmployee Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $34.57 | $0.00 |
DisclosureSEC source: 0001193805-22-001002 · e621773_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-12-10 F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on December 10, 2021, subject to approval of an amendment to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan by the Company's stockholders, which approval was obtained at the Company's 2022 Annual Meeting of Stockholders held on June 21, 2022. F2 · derivative.exercise_date: The shares underlying this option vest 25% on December 10, 2022, the first anniversary of the date this award was conditionally approved by the Board of Directors, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 16:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 8,100 | $40.00 | $324,000.00 |
DisclosureSEC source: 0001193805-22-000015 · e621194_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,448 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 16:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 3,633 | $40.00 | $145,327.63 |
DisclosureSEC source: 0001193805-21-001784 · e621144_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 16:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 6,367 | $40.00 | $254,680.00 |
DisclosureSEC source: 0001193805-21-001726 · e621144_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,181 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 11:20 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $44.41 | $444,100.00 |
DisclosureSEC source: 0001193805-21-001522 · e621049_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 1, 2021 with sale prices ranging from $43.17 to $45.42 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 17:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $44.36 | $443,600.00 |
DisclosureSEC source: 0001193805-21-001408 · e620990_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 1, 2021 with sale prices ranging from $43.04 to $47.91 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:06 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $55.86 | $558,600.00 |
DisclosureSEC source: 0001193805-21-001272 · e620921_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 1, 2021 with sale prices ranging from $53.91 to $57.26 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 16:32 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $40.07 | $400,700.00 |
DisclosureSEC source: 0001193805-21-001112 · e620845_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 642,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on August 3, 2021 with sale prices ranging from $40.00 to $40.57 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $42.95 | $429,500.00 |
DisclosureSEC source: 0001193805-21-000455 · e620448_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on April 1, 2021 with sale prices ranging from $41.55 to $44.26 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $54.23 | $542,300.00 |
DisclosureSEC source: 0001193805-21-000323 · e620351_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on March 1, 2021 with sale prices ranging from $53.34 to $55.36 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:45 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $75.31 | $753,100.00 |
DisclosureSEC source: 0001193805-21-000124 · e620251_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on February 1, 2021 with sale prices ranging from $73.19 to $76.60 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:19 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $46.40 | $464,000.00 |
DisclosureSEC source: 0001193805-21-000014 · e620192_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,548 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on January 4, 2021 with sale prices ranging from $43.74 to $50.36 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 19:40 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $99.29 | $0.00 |
DisclosureSEC source: 0001193805-20-001610 · e620164_4-chivukula.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 17:45 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $96.19 | $961,900.00 |
DisclosureSEC source: 0001193805-20-001491 · e620114_4-chivukula.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,548 F1 · price: Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on December 1, 2020 with sale prices ranging from $87.29 to $100.43 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 20:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $55.28 | $552,800.00 |
DisclosureSEC source: 0000899243-20-030320 · doc4.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,548 F1 · price: The reported price is the weighted average price per share sold by the reporting person. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on November 2, 2020 with sale prices ranging from $53.04 to $56.80 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 17:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $42.83 | $428,300.00 |
DisclosureSEC source: 0000899243-20-026884 · doc4.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,548 F1 · price: The reported price is the weighted average price per share sold by the reporting person. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on October 1, 2020 with sale prices ranging from $41.57 to $44.04 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 03, 2020 Filed Sep 4, 2020 17:05 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 10,000 | $45.16 | $451,600.00 |
DisclosureSEC source: 0000899243-20-024363 · doc4.xml · nonDerivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,548 F1 · price: The reported price is the weighted average price per share sold by the reporting person after adjustment for a broker's error. Reflects the weighted average price of 10,000 shares of common stock of Arcturus Therapeutics Holdings Inc. sold by the Reporting Person in multiple transactions on September 3, 2020 with sale prices ranging from $42.60 to $47.93 per share. The Reporting Person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 20:31 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $14.12 | $0.00 |
DisclosureSEC source: 0000899243-20-005389 · doc4.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-18 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:20 UTC | Arcturus Therapeutics Ltd. ARCT · Entity 160417 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 38,333 | $4.99 Strike: $4.99 | $191,281.67 |
DisclosureSEC source: 0001566049-19-000004 · edgardoc.xml · derivative · entry 2 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,333 Underlying: Common Stock · 38,333 shares Expires 2029-02-06 F1 · derivative.exercise_date: Vesting over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:20 UTC | Arcturus Therapeutics Ltd. ARCT · Entity 160417 | GrantIncentive Stock Option (right to buy) · Derivative | 1,667 | $4.99 Strike: $4.99 | $8,318.33 |
DisclosureSEC source: 0001566049-19-000004 · edgardoc.xml · derivative · entry 1 Chivukula Pad · CIK 0001727317 · Chief Scientific Officer & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Common Stock · 1,667 shares Expires 2029-02-06 F1 · derivative.exercise_date: Vesting over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.